Drugs / Figitumumab
Trials 22 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT00976508 | Nov 2009 → Sep 2011 | breast neoplasm, colorectal neoplasm, lung neoplasm, prostate neoplasm +1 | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00927966 | Jul 2009 → Jan 2011 | sarcoma | Suzanne George, MD | Completed | No outcome recorded |
| Phase 1 | NCT00926263 | Jul 2009 → May 2010 | — | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00728390 | Dec 2008 → Aug 2011 | metastatic neoplasm, non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00729833 | Sep 2008 → Aug 2011 | cancer of unknown primary site | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00603538 | Jan 2008 → May 2009 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00560573 | Nov 2007 → Jun 2008 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00474760 | Aug 2005 → Jan 2011 | Ewing sarcoma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01653158 | Mar 2005 → Feb 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01536145 | Dec 2003 → Jun 2008 | plasma cell myeloma | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00635245 | — | breast cancer | Pfizer | Withdrawn | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00560235 | Mar 2008 → Mar 2010 | Ewing sarcoma/peripheral primitive neuroectodermal tumor | Pfizer | Completed | No outcome recorded |
| Phase 1/2 | NCT00147537 | Feb 2005 → Aug 2011 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT00977561 | Apr 2010 → Oct 2011 | small cell lung carcinoma | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00678626 | Apr 2009 → Sep 2011 | breast cancer | Pfizer | Withdrawn | No outcome recorded |
| Phase 2 | NCT00872404 | Jan 2009 → Sep 2010 | head and neck cancer | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Terminated | No outcome recorded |
| Phase 2 | NCT00560560 | Dec 2007 → Sep 2010 | colorectal neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00372996 | Feb 2007 → Sep 2012 | breast cancer | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00313781 | May 2006 → Apr 2011 | prostate neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00907504 | Jul 2010 → May 2014 | non-small cell lung carcinoma | Pfizer | Withdrawn | No outcome recorded |
| Phase 3 | NCT00673049 | May 2008 → Mar 2011 | adenosquamous carcinoma, large cell carcinoma, non-small cell lung carcinoma | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00596830 | Apr 2008 → Mar 2011 | adenosquamous carcinoma, large cell carcinoma, non-small cell lung carcinoma | Pfizer | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Figitumumab | “Figitumumab is a fully human IgG2 monoclonal antibody against IGF-1 receptor (IGF-1R).” PMID 21748299 ↗ Jul 2011 |
| Known as | CP-750,871 | “CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be...” NCT00313781 ↗ |
| Known as | CP-751 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1743019 ↗ |
| Known as | CP-751,871 | “A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer” NCT00977561 ↗18“Figitumumab (CP-751,871), a fully human immunoglobulin G2 monoclonal antibody, inhibits the insulin-like growth factor 1 receptor (IGF-1R).” PMID 24888810 ↗ Jun 2014 “Figitumumab (CP-751,871) is a fully human IgG2 monoclonal antibody that inhibits the insulin-like growth factor 1 receptor.” PMID 25395283 ↗ Nov 2014 “CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks” NCT00728390 ↗ |
| Action | Inhibit | “anti-IGF-1R antibody” PMID 20036194 ↗ Dec 2009 |
| Modality | Monoclonal antibody | “fully human IgG2 monoclonal antibody” PMID 20036194 ↗ Dec 2009 |
| Route | Intravenous | “CP-751,871 20 mg/kg IV” NCT00147537 ↗ |
| Target | IGF1R | “targeting the insulin-like growth-factor-1 receptor (IGF-1R)” PMID 20036194 ↗ Dec 2009 |